stockrow
Saturday 7 November 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
- EPS
- −343.5%
- Free cash flow
- −74.8%
Quarter to June 2026, against a year earlier
9.30
0.36
+4.03%
Follow TTRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 3 | 6 | +389.9% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (2) | (3) | (8) | +80.6% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (2) | (3) | (8) | +80.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (0.07) | (0.12) | (0.29) | +80.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.05) | (0.09) | (0.15) | +81.0% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.01) | 0.00 | +48.6% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.05) | (0.10) | (0.15) | +78.8% | ||||||
| Book value | — | — | — | — | — | — | — | — | (0.01) | 0.17 | 0.02 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 27 | 28 | 29 | +4.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (3) | (4) | +88.3% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | +53.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (3) | (4) | +85.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 0 | (1) | 2 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (1) | (5) | (4) | +481.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 0 | 5 | 1 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (44.95) | (99.59) | (44.9) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (141.67) | (3,315.33) | (141.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 2 | 2 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Turn Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OCGN Ocugen, Inc. | $276.9M | — (loss-making) | — (loss-making) | +11.36% (above 0%: growing) | n/m | −22.15% (below 0%: shrinking) | 100.00% | (909.94%) | Compare |
| DTIL Precision BioSciences, Inc. | $275.7M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | −0.52% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NAUT Nautilus Biotechnology, Inc. | $273.9M | — (loss-making) | — | — | n/m | −28.59% (below 0%: shrinking) | 89.74% | (7,152.56%) | Compare |
| IPSC Century Therapeutics, Inc. | $273.4M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| TTRX Turn Therapeutics Inc. | $273.0M | — (loss-making) | — | — | n/m | −74.76% (below 0%: shrinking) | — | 0.00% | |
| VOGX Vogenx Inc | $270.8M | — | — | — | n/m | — | — | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $267.5M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RCKT Rocket Pharmaceuticals, Inc. | $267.3M | — (loss-making) | — | — | n/m | +19.16% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ARCT Arcturus Therapeutics Holdings Inc. | $266.0M | — (loss-making) | — (loss-making) | +6.68% (above 0%: growing) | n/m | +59.86% (above 0%: growing) | 100.00% | (50.20%) | Compare |
| Median of peers | $272.1M | — | — | +11.36% | — | −0.52% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 19 October 2026
Ownership
Directors and executive officers, together
55.89%
Bradley Burnam
49.51%
BEB Holdings, LLC
49.51%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement